COLORADO SPRINGS, Colo.,
Aug. 4, 2014 /PRNewswire/
-- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company
specializing in cannabis formulation-based drug development and
related consulting is announcing that through its wholly-owned
subsidiary, Cannabis Science International Holding BV, has signed
an agreement with the prestigious Institute for Research,
Hospitalization and Health Care on Ageing (INRCA) in Italy. The agreement provides for toxicity and
efficacy studies of cannabinoid formulations performed in animal
models for neurobehavioral diseases including sleep
disorders.
The first formulation in the series of neurobehavioral
disorder-targeted products is in the pre-clinical development
stage.
"We are excited to be initiating research on cannabinoids with
Cannabis Science; the preliminary results are promising," said
Marco Malavolta, the INRCA
researcher in charge of the pre-clinical study. Dr. Malavolta
is an expert in the field of nutrition, ageing and longevity and he
is currently conducting research with Dr. Mauro Provinciali (Head of Laboratory) on
nutritional factors that affect cellular aging, a process also
known as cellular senescence. They are undergoing their research at
the Nutrition and Ageing Centre of the Scientific and Technological
Pole of INRCA, a department with a long historical background in
multiple aspects of gerontology research.
"We appreciate the scientific input from the INRCA colleagues in
Italy and hope that we will be
able to transition into clinical this program next year," noted
Mario Lap, Director and President of European Operations, Cannabis
Science, Inc.
About the Institute for Research, Hospitalization and Health
(IRCCS)
The Italian Institute for Health and Science on
Ageing (INRCA) works in the area of geriatrics and gerontology
studies, with the aim of protecting the health of the
elderly. INRCA not only serves as a health resource of
excellence but also supports research on basic mechanisms of
longevity, the fragility of the elderly and the determinants of
genetic, biological and environmental impacts of major age-related
diseases. In this context, among the primary objectives of the
Institute is to develop innovative and interdisciplinary research
in the areas of basic biomedical, clinical, social, and
organization of services.
About Cannabis Science, Inc.
Cannabis Science, Inc.,
takes advantage of its unique understanding of metabolic processes
to provide novel treatment approaches to a number of illnesses for
which current treatments and understanding remain unsatisfactory.
Cannabinoids have an extensive history dating back thousands of
years, and currently there are a growing number of peer-reviewed
scientific publications that document the underlying biochemical
pathways that cannabinoids modulate. The Company works with leading
experts in drug development, medicinal characterization, and
clinical research to develop, produce, and commercialize novel
therapeutic approaches for the treatment for illnesses caused by
infections as well as for age-related illness. Our initial focus is
on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing words such as "anticipate," "seek,"
intend," "believe," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. Some or all of the events or results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include the future U.S. and
global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development
of cannabis-based drugs. Cannabis Science, Inc., does not undertake
any duty nor does it intend to update the results of these
forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
dorothy.bray@cannabisscience.com
info@cannabisscience.com
Tel: 1.888.777.0658
Investment Inquiries
Robert Kane, CFO & Director
robert.kane@cannabisscience.com
Tel: 1.561.420.4824
Cannabis Science, Inc.
Raymond C. Dabney, Management
Consultant, Co-Founder
raymond@cannabisscience.com
Tel: 1.310.650.3788
SOURCE Cannabis Science, Inc.